CYTO
Income statement / Annual
Last year (2023), Altamira Therapeutics Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Altamira Therapeutics Ltd.'s net income was -$7.27 M.
See Altamira Therapeutics Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$305.62 K |
$63.88 K |
$174.48 K |
-$56.00 K |
$1.27 M |
$322.00 K |
-$414.00 K |
-$67.00 K |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.44 M
|
$2.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$1.14 M
|
-$2.18 M
|
$174.48 K
|
-$56.00 K
|
$1.27 M
|
$322.00 K
|
-$414.00 K
|
-$67.00 K
|
$3.01 M
|
| Gross Profit Ratio |
0
|
-3.72
|
-34.07
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$3.04 M
|
$14.62 M
|
$3.20 M
|
$2.86 M
|
$3.33 M
|
$6.69 M
|
$19.21 M
|
$24.78 M
|
$26.54 M
|
$17.70 M
|
| General & Administrative Expenses |
$3.09 M
|
$3.38 M
|
$3.58 M
|
$2.60 M
|
$3.93 M
|
$4.27 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
| Selling & Marketing Expenses |
$15.35 K
|
$15.73 K
|
$39.92 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.12 M
|
$3.39 M
|
$3.62 M
|
$2.60 M
|
$3.93 M
|
$4.27 M
|
$5.15 M
|
$5.41 M
|
$4.34 M
|
$4.49 M
|
| Other Expenses |
$0.00
|
$112.67 K
|
$30.43 K
|
-$175.00 K
|
$0.00
|
$0.00
|
$87.59 K
|
$34.06 K
|
$62.20 K
|
$73.43 K
|
| Operating Expenses |
$6.54 M
|
$18.01 M
|
$6.87 M
|
$5.28 M
|
$7.26 M
|
$10.95 M
|
$24.36 M
|
$30.22 M
|
$30.88 M
|
$22.19 M
|
| Cost And Expenses |
$6.54 M
|
$18.01 M
|
$6.87 M
|
$5.46 M
|
$7.26 M
|
$10.95 M
|
$24.36 M
|
$30.22 M
|
$30.88 M
|
$22.19 M
|
| Interest Income |
$730.20 K
|
$114.27 K
|
$26.99 K
|
$258.00
|
$17.88 K
|
$0.00
|
$53.57 K
|
$67.57 K
|
$37.00 K
|
$3.68 K
|
| Interest Expense |
$0.00
|
$911.87 K
|
$14.11 K
|
$135.15 K
|
$28.63 K
|
$1.07 M
|
$1.64 M
|
$828.55 K
|
$8.00 K
|
$49.64 K
|
| Depreciation & Amortization |
$5.92 M
|
$118.89 K
|
$76.36 K
|
$20.04 K
|
$30.82 K
|
$72.71 K
|
$122.78 K
|
$97.60 K
|
$92.78 K
|
$73.98 K
|
| EBITDA |
-$1.35 M |
-$17.64 M |
-$6.72 M |
-$8.07 M |
-$6.77 M |
-$10.95 M |
-$24.31 M |
-$30.06 M |
-$30.84 M |
-$22.19 M |
| EBITDA Ratio |
0
|
-57.71
|
-105.13
|
-46.23
|
120.82
|
-8.65
|
-75.49
|
72.6
|
460.31
|
0
|
| Operating Income Ratio |
0
|
-58.94
|
-83.61
|
-30.28
|
129.63
|
-8.65
|
-75.66
|
73
|
460.86
|
0
|
| Total Other Income/Expenses Net |
-$1.35 M
|
-$646.00 K
|
-$1.46 M
|
-$2.94 M
|
$433.41 K
|
-$380.00 K
|
-$66.00 K
|
-$570.00 K
|
$1.17 M
|
$4.01 M
|
| Income Before Tax |
-$7.27 M
|
-$18.66 M
|
-$6.81 M
|
-$8.22 M
|
-$6.83 M
|
-$11.33 M
|
-$24.43 M
|
-$30.79 M
|
-$29.71 M
|
-$18.19 M
|
| Income Before Tax Ratio |
0
|
-61.06
|
-106.54
|
-47.12
|
121.89
|
-8.95
|
-75.86
|
74.38
|
443.36
|
0
|
| Income Tax Expense |
$0.00
|
-$10.33 K
|
-$117.95 K
|
-$21.28 K
|
-$194.00 K
|
$162.18 K
|
-$17.77 K
|
-$131.00 K
|
-$84.78 K
|
$0.00
|
| Net Income |
-$7.27 M
|
-$26.53 M
|
-$17.06 M
|
-$8.20 M
|
-$6.63 M
|
-$11.50 M
|
-$24.41 M
|
-$30.66 M
|
-$29.71 M
|
-$18.19 M
|
| Net Income Ratio |
0
|
-86.8
|
-267.03
|
-47
|
118.43
|
-9.08
|
-75.8
|
74.06
|
443.36
|
0
|
| EPS |
-14.81 |
-582.58 |
-515.11 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
| EPS Diluted |
-14.8 |
-582.58 |
-515.11 |
-545.41 |
-455.96 |
-2892.03 |
-22322.34 |
-35728.56 |
-36790.93 |
-26267.51 |
| Weighted Average Shares Out |
$491.00 K
|
$45.54 K
|
$33.12 K
|
$15.04 K
|
$14.55 K
|
$3.98 K
|
$1.09 K
|
$858.20
|
$807.40
|
$692.30
|
| Weighted Average Shares Out Diluted |
$491.26 K
|
$45.54 K
|
$33.12 K
|
$15.04 K
|
$14.55 K
|
$3.98 K
|
$1.09 K
|
$858.20
|
$807.40
|
$692.30
|
| Link |
|
|
|
|
|
|
|
|
|
|
